Beximco Pharmaceuticals Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Iqbal Ahmed

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	39.8yrs
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	15.5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.2yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Iqbal Ahmed

39.8yrs

Amtszeit

Mr. Iqbal U. Ahmed is MD of Beximco Pharmaceuticals Limited and serves as its Director since 1985. has been a Director of Shinepukur Ceramics Limited since August 24, 2012 and Non-Executive Director at Ban...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Iqbal Ahmed	MD & Director	no data	keine Daten	keine Daten
Mohammad Nawaz	Chief Financial Officer	15.8yrs	keine Daten	keine Daten
S. M. Reza	Chief Operating Officer	15.5yrs	keine Daten	keine Daten
Jamal Choudhury	Director of Accounts & Finance	no data	keine Daten	keine Daten
Rizvi Kabir	Director of Marketing	no data	keine Daten	keine Daten
M. A. Bhuiyan	General Manager of Human Resources	no data	keine Daten	keine Daten
Zakaria Chowdhury	Head of Distribution Services & Director of International Marketing	14.8yrs	keine Daten	keine Daten
Mohammad Ullah	Company Secretary & Executive Director	no data	keine Daten	keine Daten

15.5yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: BXPHARMADas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (15.5 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Iqbal Ahmed	MD & Director	39.8yrs	keine Daten	keine Daten
Mohammad Ullah	Company Secretary & Executive Director	no data	keine Daten	keine Daten
Salman Rahman	Vice Chairman	no data	keine Daten	2.04% BDT 724.6m
Abu Bakar Rahman	Director	31.8yrs	keine Daten	keine Daten
Osman Chowdhury	Director	no data	keine Daten	keine Daten
Ahmed Sohail Rahman	Chairman	no data	keine Daten	2.03% BDT 722.9m
Quamrun Ahmed	Non-Executive Director	4yrs	keine Daten	keine Daten
Mamtaz Ahmed	Independent Non-Executive Director	4.3yrs	keine Daten	keine Daten
Reem Shamsuddoha	Non-Executive Director	4yrs	keine Daten	keine Daten
Md. Hosein Khan	Independent Director	3.8yrs	keine Daten	keine Daten

4.2yrs

Durchschnittliche Betriebszugehörigkeit

64yo

Durchschnittliches Alter

Erfahrener Vorstand: BXPHARMADie Vorstandsmitglieder gelten als erfahren (4.2 Jahre durchschnittliche Amtszeit).

Beximco Pharmaceuticals Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Beximco Pharmaceuticals Limited, Annual General Meeting, Dec 29, 2024

Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Managing Director

Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Member of the Board

Beximco Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Full year 2024 earnings: EPS exceeds analyst expectations

Beximco Pharmaceuticals Limited to Report Q1, 2025 Results on Nov 13, 2024

Dividend of ৳4.00 announced

Beximco Pharmaceuticals Limited, Annual General Meeting, Dec 29, 2024

Beximco Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Oct 28, 2024

Price target increased by 9.3% to ৳168

Third quarter 2024 earnings released: EPS: ৳3.06 (vs ৳2.13 in 3Q 2023)

Beximco Pharmaceuticals Limited to Report Q3, 2024 Results on Apr 29, 2024

Second quarter 2024 earnings released: EPS: ৳3.21 (vs ৳2.77 in 2Q 2023)

Beximco Pharmaceuticals Limited to Report Q2, 2024 Results on Jan 29, 2024

Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Managing Director

Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Member of the Board

Upcoming dividend of ৳3.50 per share at 2.4% yield

Full year 2023 earnings released: EPS: ৳10.34 (vs ৳11.48 in FY 2022)

Beximco Pharmaceuticals Limited to Report Q1, 2024 Results on Nov 05, 2023

Beximco Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023

Beximco Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Oct 19, 2023

Third quarter 2023 earnings released: EPS: ৳2.13 (vs ৳2.47 in 3Q 2022)

Second quarter 2023 earnings released: EPS: ৳2.77 (vs ৳3.84 in 2Q 2022)

Beximco Pharmaceuticals Limited Announces Cash Dividend for the Year Ended June 30, 2022

Less than half of directors are independent

Full year 2022 earnings: EPS misses analyst expectations

Beximco Pharmaceuticals Limited Proposes Dividend for the Year Ended 30 June 2022

Third quarter 2022 earnings: EPS exceeds analyst expectations

Price target increased to ৳182

Less than half of directors are independent

Now 20% undervalued after recent price drop

Consensus EPS estimates increase by 18%

Second quarter 2022 earnings: EPS exceeds analyst expectations

Beximco Pharmaceuticals Limited Launches First Generic Version of Pfizer's COVID-19 Treatment Paxlovid

Upcoming dividend of ৳3.50 per share

Full year 2021 earnings released: EPS ৳11.49 (vs ৳7.88 in FY 2020)

Third quarter 2021 earnings released: EPS ৳3.28 (vs ৳2.02 in 3Q 2020)

Investor sentiment improved over the past week

Beximco Pharmaceuticals Limited Updates on the Supply of Covid-19 Vaccine

Second quarter 2021 earnings released: EPS ৳2.54 (vs ৳1.93 in 2Q 2020)

Analysts increase EPS estimates to ৳10.32

Price target raised to ৳114

Beximco Pharmaceuticals Limited Announces Board Changes

Beximco Pharmaceuticals Limited Provides Update on the Supply of COVID-19 Vaccine

Beximco Pharmaceuticals Limited Confirms Quamrun Naher Ahmed and Reem H. Shamsuddoha as Non-Executive Directors

Investor sentiment improved over the past week

New 90-day high: ৳170

New 90-day high: ৳159

Beximco Pharmaceuticals Limited Announces Directors Appointments

New 90-day high: ৳148

Price target raised to ৳113

New 90-day high: ৳148

Price target raised to ৳116

New 90-day high: ৳145

First quarter 2021 earnings released: EPS ৳2.65

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS ৳8.67

Beximco Pharmaceuticals Limited Enters into A Memorandum of Understanding for the Supply and Distribution of 30 Million Doses of the Oxford University/AstraZeneca SARS-CoV-2 Vaccine, AZD1222, in Bangladesh

New 90-day high: ৳127

Beximco Pharmaceuticals Limited Receives US Food and Drug Administration (Fda) Approval for Antiarryhtmic Drug Flecainide

Price target raised to ৳105

New 90-day high - ৳116

Geschäftsführer

Amtszeit

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter